Lumateperone

From WikiMD's Wellness Encyclopedia

Lumateperone (also known as ITI-007) is an antipsychotic medication developed by Intra-Cellular Therapies for the treatment of schizophrenia, bipolar disorder, and depression. It was approved by the FDA in December 2019 for the treatment of schizophrenia in adults.

Mechanism of Action[edit | edit source]

Lumateperone acts as a serotonin receptor antagonist, dopamine receptor phosphoprotein modulator, and glutamate receptor modulator. It has a unique mechanism of action that differs from other antipsychotic drugs.

Medical Uses[edit | edit source]

Lumateperone is used primarily for the treatment of schizophrenia in adults. It is also being investigated for potential use in treating bipolar disorder and depression.

Side Effects[edit | edit source]

Common side effects of lumateperone include somnolence, nausea, dry mouth, and weight gain. Serious side effects may include neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension.

History[edit | edit source]

Lumateperone was developed by Intra-Cellular Therapies and received FDA approval in December 2019. It is marketed under the brand name Caplyta.

See Also[edit | edit source]

References[edit | edit source]


Lumateperone Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD